|Ms. Emma Natasha Walmsley||CEO & Director||4.79M||1.16M||1970|
|Ms. Julie Belita Brown||CFO & Executive Director||N/A||N/A||1962|
|Ms. Shobie Ramakrishnan||Chief Digital & Technology Officer||N/A||N/A||N/A|
|Mr. Tony Wood||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Sarah Elton-Farr||Head of Investor Relations||N/A||N/A||N/A|
|Mr. James Ford||Senior VP & Group General Counsel of Legal & Compliance||N/A||N/A||N/A|
|Ms. Sally Jackson||Senior Vice President of Global Communications & CEO Office||N/A||N/A||N/A|
|Mr. David Simon Redfern BSc (Hons), CA||President of Corporate Development||N/A||N/A||1966|
|Ms. Diana Conrad||Chief People Officer||N/A||N/A||N/A|
|Mr. Philip C. Thomson||President of Global Affairs||N/A||N/A||N/A|
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
GSK plc’s ISS governance QualityScore as of 28 November 2023 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 1; Compensation: 9.